Syrris Celebrates 15 Years of Chemisty Innovation
News Aug 23, 2016
Syrris is celebrating 15 years of creating pioneering chemistry solutions. Founded in August 2001 to address some of the technology challenges faced by the pharmaceutical industry, the company’s focus on improving productivity in R&D chemistry has ensured that it rapidly became a leading provider across various sectors, such as the pharmaceutical manufacturing, petrochemistry, agrochemistry and fine chemical synthesis industries.
Today, Syrris has grown into a world leader in the field of flow chemistry, with a dedicated and highly capable team of engineers and scientists. Offering a versatile range of automated flow and batch chemistry solutions for a broad range of applications – from synthesis, process optimization and reaction analysis to crystallization, calorimetry and scale-up – it continues to deliver innovative products combining cutting-edge technologies with ease of use.
Mark Gilligan, Chief Executive Officer and Chairman of Blacktrace Holdings, commented: “We are very pleased to reach this milestone, and continue to enjoy year on year growth. Our industry-focused approach has ensured we can deliver solutions to meet the day-to-day challenges faced by research and development chemists and chemical engineers, while continuing to combine our science and product engineering capabilities to develop innovative products.”
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE